2026 Aug 13
Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study.

Progression to Wheelchair in Secondary Progressive Multiple Sclerosis and Impact of Siponimod: Post Hoc Analyses From the EXPAND Study.
Vermersch P, Arnould S, Gold R, Kappos L, Fox R, Bar-Or A, Cree BAC, Ansari S, Meier DP, Karlsson G, Rouyrre N, Giovannoni G.
Eur J Neurol. 2026 Jun1.

Anti-inflammatory Effects of Siponimod in a Mouse Model of Excitotoxicity-Induced Retinal Injury. Basavarajappa D, Gupta V, Chitranshi N, Viswanathan D, Gupta V, Vander Wall R, Palanivel V, Mirzaei M, You Y, Klistorner A, Graham SL.
Mol Neurobiol. 2023 Aug 5. doi: 10.1007/s12035-023-03535-0. Online ahead of print.
PMID: 37542647
2.
Effect of siponimod on retinal thickness, a marker of neurodegeneration, in participants with SPMS: Findings from the EXPAND OCT substudy. Mousseau MC, Maio-Twofoot T, Shi X, Kappos L.
Mult Scler Relat Disord. 2025 Jan 4
3.
Siponimod supports remyelination in the non-supportive environment.
Siponimod podporuje remyelinizaci v nepodporujícím prostředí.
Sci Rep. 2025 Feb 4 4.
Siponimod inhibits microglial inflammasome activation. Komiya H, Takeuchi H, Ogasawara A, Siponimod inhibuje aktivaci mikrogliálního zánět
Neurosci Res. 2025 Feb 5
Progression to Wheelchair in Secondary Progressive Multiple Sclerosis and Impact of Siponimod: Post Hoc Analyses From the EXPAND Study.
Vermersch P, Arnould S, Gold R, Kappos L, Fox R, Bar-Or A, Cree BAC, Ansari S, Meier DP, Karlsson G, Rouyrre N, Giovannoni G.
Eur J Neurol. 2026 Jun